生物制剂治疗银屑病复发的研究现状

doi:10.35541/cjd.20230301

中华皮肤科杂志 ›› 2025, e20230301.doi: 10.35541/cjd.20230301

生物制剂治疗银屑病复发的研究现状

王文秋¹ 李承新² 王睿²

¹解放军医学院，北京 100853；²解放军总医院第一医学中心皮肤科，北京 100853

收稿日期:2023-05-26 修回日期:2024-08-14 发布日期:2025-02-10
通讯作者: 王睿 E-mail:wangruiderm@163.com
基金资助:
国家自然科学基金（82273530）；北京市自然科学基金（7224344）

Biologics for the treatment of psoriasis relapse: current status

Wang Wenqiu¹, Li Chengxin², Wang Rui²

¹Medical School of Chinese PLA, Beijing 100853, China; ²Department of Dermatology, the 1th Medical Center, Chinese PLA General Hospital, Beijing 100853, China

Received:2023-05-26 Revised:2024-08-14 Published:2025-02-10
Contact: Wang Rui E-mail:wangruiderm@163.com
Supported by:
National Natural Science Foundation of China（82273530）; Beijing Municipal Natural Science Foundation （7224344）

摘要/Abstract

摘要： 【摘要】银屑病是一种慢性、复发性、系统性、炎症性疾病。在过去的20年中，伴随靶向肿瘤坏死因子或肿瘤坏死因子受体、白细胞介素17A（IL-17A）或IL-17A受体、IL-23等生物制剂的开发和应用，银屑病的治疗取得巨大进展。但在停止生物制剂治疗后或在维持治疗期间，复发仍是银屑病治疗面临的一大挑战。本文综述生物制剂治疗后银屑病的复发情况，并提出预防复发的综合管理建议。

关键词: 银屑病, 复发, 生物制剂, 肿瘤坏死因子抑制剂, 白细胞介素抑制剂, 病人医护管理, 综合预防

Abstract: 【Abstract】 Psoriasis is a chronic, recurrent, systemic, inflammatory disease. Over the past 20 years, with the development and application of biologics targeting tumor necrosis factor （TNF） or TNF receptors, interleukin-17A （IL-17A） or IL-17A receptors, IL-23, and others, significant progress has been made in the treatment of psoriasis. However, recurrence remains a major challenge in the management of psoriasis after discontinuation of biologic therapy or during maintenance treatment. This review summarizes the recurrence of psoriasis following biologic treatment and proposes comprehensive management recommendations to prevent its recurrence.

Key words: Psoriasis, Recurrence, Biological agents, Tumor necrosis factor inhibitors, Interleukin inhibitors, Patient care management, Universal precautions

王文秋李承新王睿. 生物制剂治疗银屑病复发的研究现状[J]. 中华皮肤科杂志, 2025,e20230301. doi:10.35541/cjd.20230301

Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status[J]. Chinese Journal of Dermatology,2025,e20230301. doi:10.35541/cjd.20230301

参考文献 50

［1］	Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis［J］. Lancet, 2007,370（9583）:263⁃271. doi: 10.1016/S0140⁃6736（07）61128⁃3.
［2］	Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician［J］. Biologics, 2021,15:39⁃51. doi: 10.2147/BTT.S252578.
［3］	Committee on Psoriasis, Dermatology and Venereology Branch of the Chinese Medical Association. Expert consensus on the Treat⁃to⁃Target strategy for psoriasis with biological agents in China （simplified edition）［J］. Int J Dermatol Venerol, 2024,7（2）:61⁃69. doi: 10.1097/JD9.0000000000000300.
［4］	Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries［J］. JID Innov, 2022,2（3）:100116. doi: 10.1016/j.xjidi.2022.100116.
［5］	Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies［J］. J Allergy Clin Immunol, 2017,140（3）:645⁃653. doi: 10.1016/j.jaci.2017.07.004.
［6］	Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis［J］. Int J Mol Sci, 2020,21（20）:7488. doi: 10.3390/ijms21207488.
［7］	Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management［J］. J Psoriasis Psoriatic Arthritis, 2019,4（2）:70⁃80. doi: 10.1177/2475530318810851.
［8］	Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors［M］. Treasure Island （FL）: StatPearls Publishing, 2022.
［9］	Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phaseⅢ, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）:1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6.
［10］	Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phaseⅡ randomized, placebo⁃controlled trial with a re⁃treatment extension［J］. Br J Dermatol, 2012,167（1）:180⁃190. doi: 10.1111/j.1365⁃2133.2012.10941.x.
［11］	Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phaseⅢ trial［J］. J Am Acad Dermatol, 2008,58（1）:106⁃115. doi: 10. 1016/j.jaad.2007.09.010.
［12］	Tse MT. IL⁃17 antibodies gain momentum［J］. Nat Rev Drug Discov, 2013,12（11）:815⁃816. doi: 10.1038/nrd4152.
［13］	Bartlett HS, Million RP. Targeting the IL⁃17⁃T（H）17 pathway［J］. Nat Rev Drug Discov, 2015,14（1）:11⁃12. doi: 10.1038/nrd4518.
［14］	Branisteanu DE, Cojocaru C, Diaconu R, et al. Update on the etiopathogenesis of psoriasis （review）［J］. Exp Ther Med, 2022,23（3）:201. doi: 10.3892/etm.2022.11124.
［15］	Lowes MA, Suárez⁃Fariñas M, Krueger JG. Immunology of psoriasis［J］. Annu Rev Immunol, 2014,32:227⁃255. doi: 10.1146/annurev⁃immunol⁃032713⁃120225.
［16］	Crowley JJ, Warren RB, Cather JC. Safety of selective IL⁃23p19 inhibitors for the treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1676⁃1684. doi: 10.1111/jdv.15653.
［17］	Ghazawi FM, Mahmood F, Kircik L, et al. A review of the efficacy and safety for biologic agents targeting il⁃23 in treating psoriasis with the focus on tildrakizumab［J］. Front Med （Lausanne）, 2021,8:702776. doi: 10.3389/fmed.2021.702776.
［18］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phaseⅢ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［19］	Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
［20］	Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments［J］. Arch Dermatol, 2005,141（1）:82⁃84. doi: 10.1001/archderm.141.1.82.
［21］	Khemis A, Kelati A, Montaudié H, et al. Successful treatment of severe psoriasis relapse with secukinumab （interleukin 17 A inhibitor） after abrupt brodalumab （interleukin 17 receptor inhibitor） discontinuation: a retrospective study evaluating long⁃term efficacy and safety［J］. J Am Acad Dermatol, 2018,79（4）:758⁃760. doi: 10.1016/j.jaad.2018.03.027.
［22］	Masson Regnault M, Konstantinou MP, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients［J］. J Eur Acad Dermatol Venereol, 2017,31（9）:1491⁃1496. doi: 10.1111/jdv.14387.
［23］	Ortonne JP, Taïeb A, Ormerod AD, et al. Patients with moderate⁃to⁃severe psoriasis recapture clinical response during re⁃treatment with etanercept［J］. Br J Dermatol, 2009,161（5）:1190⁃1195. doi: 10.1111/j.1365⁃2133.2009.09238.x.
［24］	Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate⁃to⁃severe psoriasis［J］. N Engl J Med, 2010,362（2）:118⁃128. doi: 10.1056/NEJMoa 0810652.
［25］	Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2020,156（6）:649⁃658. doi: 10.1001/jamadermatol.2020.0723.
［26］	Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate⁃to⁃severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:919⁃927. doi: 10.1111/jdv.16964.
［27］	Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phaseⅢ studies［J］. Br J Dermatol, 2020,182（6）:1359⁃1368. doi: 10.1111/bjd.18484.
［28］	Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum il⁃23⁃regulated il⁃17 and il⁃22 in psoriasis: VOYAGE 2 study［J］. J Invest Dermatol, 2019,139（12）:2437⁃2446.e1. doi: 10.1016/j.jid.2019.05.016.
［29］	Rivera R, Martorell A, López A, et al. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study［J］. J Eur Acad Dermatol Venereol, 2021,35（1）:e65⁃e67. doi: 10. 1111/jdv.16809.
［30］	Chiu HY, Hui RC, Tsai TF, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8⁃year multicenter study［J］. J Am Acad Dermatol, 2023,88（1）:71⁃78. doi: 10.1016/j.jaad.2019. 01.035.
［31］	Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment⁃as⁃needed versus fixed⁃interval maintenance regimen for moderate to severe plaque psoriasis:a randomized, double⁃blind, noninferiority trial （SCULPTURE）［J］. J Am Acad Dermatol, 2015,73（1）:27⁃36. doi: 10.1016/j.jaad.2015.04.011.
［32］	Blauvelt A, Reich K, Warren RB, et al. Secukinumab re⁃initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis［J］. Br J Dermatol, 2017,177（3）:879⁃881. doi: 10.1111/bjd.15656.
［33］	Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（6）:1004⁃1013. doi: 10.1111/jdv.14163.
［34］	Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy［J］. Br J Dermatol, 2011,164（2）:434⁃441. doi: 10.1111/j.1365⁃2133.2010.10139.x.
［35］	Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021.
［36］	Demirbaş A, Kurtipek GS, Tunçez A, et al. The role of cystatin⁃C and fetuin⁃A in the determination of early atherosclerotic risk in psoriasis patients［J］. Dermatol Ther, 2020,33（6）:e13898. doi: 10.1111/dth.13898.
［37］	Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis［J］. Arch Dermatol, 1992,128（1）:39⁃42.
［38］	Dileepan T, Linehan JL, Moon JJ, et al. Robust antigen specific th17 T cell response to group A Streptococcus is dependent on IL⁃6 and intranasal route of infection［J］. PLoS Pathog, 2011,7（9）:e1002252. doi: 10.1371/journal.ppat.1002252.
［39］	Rendon A, Schäkel K. Psoriasis pathogenesis and treatment［J］. Int J Mol Sci, 2019,20（6）:1475. doi: 10.3390/ijms20061475.
［40］	Suárez⁃Fariñas M, Fuentes⁃Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease⁃related genes［J］. J Invest Dermatol, 2011,131（2）:391⁃400. doi: 10.1038/jid.2010.280.
［41］	Tomalin LE, Russell CB, Garcet S, et al. Short⁃term transcriptional response to IL⁃17 receptor⁃A antagonism in the treatment of psoriasis［J］. J Allergy Clin Immunol, 2020,145（3）:922⁃932. doi: 10.1016/j.jaci.2019.10.041.
［42］	Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and T⁃cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab［J］. The Journal of Investigative Dermatology, 2021,141（7）: 1707⁃1718.e9. doi: 10.1016/j.jid.2021.01.005.
［43］	Puig L, Costanzo A, Muñoz⁃Elías EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models［J］. Br J Dermatol, 2022,186（5）:773⁃781. doi: 10.1111/bjd.20963.
［44］	Henno A, Blacher S, Lambert C, et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque⁃type psoriasis［J］. Br J Dermatol, 2009,160（3）:581⁃590. doi: 10.1111/j.1365⁃2133.2008.08889.x.
［45］	Dressler C, Lambert J, Grine L, et al. Therapeutic patient education and self⁃management support for patients with psoriasis ⁃ a systematic review［J］. J Dtsch Dermatol Ges, 2019,17（7）:685⁃695. doi: 10.1111/ddg.13840.
［46］	Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents［J］. J Am Acad Dermatol, 2019,80（1）:27⁃40. doi: 10.1016/j.jaad.2018.06.057.
［47］	Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021, 397（10281）: 1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［48］	Chisholm A, Nelson PA, Pearce CJ, et al. Motivational interviewing⁃based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well（®） study［J］. Br J Dermatol, 2017,176（3）:677⁃686. doi: 10.1111/bjd. 14837.
［49］	Blackstone B, Patel R, Bewley A. Assessing and improving psychological well⁃being in psoriasis: considerations for the clinician［J］. Psoriasis （Auckl）, 2022,12:25⁃33. doi: 10.2147/PTT.S328447.
［50］	Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis［J］. J Am Acad Dermatol, 1989,20（1）:53⁃63. doi: 10. 1016/s0190⁃9622（89）70007⁃4.

[1]	于金蕾吴桥芳孙悦鑫包军周映. 佩索利单抗治疗6例泛发性脓疱型银屑病临床观察[J]. 中华皮肤科杂志, 2025, 0(5): 20240440-e20240440.
[2]	中华医学会皮肤性病学分会银屑病学组. [开放获取] 阿普米司特治疗银屑病专家指导意见（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 416-424.
[3]	中国医师协会皮肤科医师分会中华医学会皮肤病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415.
[4]	李紫钰鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383.
[5]	许秋云纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 中华皮肤科杂志, 2025, 58(4): 369-373.
[6]	中国医师协会皮肤科医师分会儿童学组中华医学会皮肤性病学分会银屑病学组. 【开放获取】儿童脓疱型银屑病诊疗中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(4): 297-306.
[7]	何春霞晋红中. 【开放获取】急危重皮肤病的诊疗原则、现状、挑战和展望[J]. 中华皮肤科杂志, 2025, 58(4): 307-314.
[8]	木葵郭慧文海泉龙海刘昱罗帅寒天黄馨周星雨肖嵘李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327.
[9]	李秀珍徐秀莲. 白细胞介素23抑制剂治疗对银屑病共病的影响[J]. 中华皮肤科杂志, 2025, 58(3): 268-272.
[10]	陈良宏孙艳王敬玉吴严. 本维莫德在皮肤病中的研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 266-268.
[11]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881.
[12]	叶慧邓仕琳梁景耀张锡宝. 特应性皮炎复发控制与组织驻留记忆性T细胞的相关性研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240192-e20240192.
[13]	李翔倩张建中周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240247-e20240247.
[14]	薛珂陈佳李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240530-e20240530.
[15]	王彩霞徐凡石晶朱海莲卢桂玲王红梅. 奥马珠单抗和度普利尤单抗治疗大疱性类天疱疮的疗效和安全性系统综述[J]. 中华皮肤科杂志, 2025, 0(3): 20220929-e0220929.

生物制剂治疗银屑病复发的研究现状

Biologics for the treatment of psoriasis relapse: current status

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 50

相关文章 15

Metrics

本文评价

推荐阅读 10